Patents Assigned to 1149336 Ontario Inc.
-
Patent number: 9044424Abstract: The present invention provides methods for modification and regulation of glucose metabolism by administering to an animal a therapeutically effective amount of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof, where the inhibitor has a Ki for inhibition of DPIV of 10 nM or less; and the inhibitor is administered in an amount sufficient to increase the plasma half-life of glucagon-like peptide 1 (GLP-1) but not sufficient to suppress the immune system of the animal.Type: GrantFiled: July 25, 2013Date of Patent: June 2, 2015Assignees: 1149336 Ontario, Inc., New England Medical Center Hospitals. Inc., Trustees of Tufts CollegeInventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
-
Patent number: 8933039Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.Type: GrantFiled: June 15, 2010Date of Patent: January 13, 2015Assignees: NPS Pharmaceuticals, Inc., 1149336 Ontario Inc.Inventors: Daniel J Drucker, Anna E. Crivici, Martin Sumner-Smith
-
Patent number: 8846625Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.Type: GrantFiled: March 11, 2013Date of Patent: September 30, 2014Assignee: 1149336 Ontario Inc.Inventors: Daniel J Drucker, Anna E. Crivici, Martin Sumner-Smith
-
Publication number: 20140213518Abstract: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.Type: ApplicationFiled: November 5, 2013Publication date: July 31, 2014Applicant: 1149336 Ontario Inc.Inventor: Daniel J. Drucker
-
Publication number: 20140178472Abstract: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.Type: ApplicationFiled: July 25, 2013Publication date: June 26, 2014Applicants: Trustees of Tufts College, 1149336 Ontario, Inc., New England Medical Center Hospitals, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
-
Patent number: 8603976Abstract: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.Type: GrantFiled: August 30, 2012Date of Patent: December 10, 2013Assignee: 1149336 Ontario, Inc.Inventor: Daniel J. Drucker
-
Patent number: 8513190Abstract: The present invention provides methods for modification and regulation of type II diabetes by administering to an animal a therapeutically effective amount of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof, where the inhibitor has a Ki for inhibition of DPIV of 10 nM or less; and the inhibitor is administered in an amount sufficient to treat type II diabetes but not sufficient to suppress the immune system of the animal.Type: GrantFiled: November 16, 2011Date of Patent: August 20, 2013Assignees: Trustees of Tufts College, New England Medical Center Hospitals, Inc., 1149336 Ontario, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
-
Publication number: 20130203673Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.Type: ApplicationFiled: March 11, 2013Publication date: August 8, 2013Applicants: 1149336 Ontario, Inc., NPS Pharmaceuticals, Inc.Inventors: NPS Pharmaceuticals, Inc., 1149336 Ontario, Inc.
-
Publication number: 20120328527Abstract: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.Type: ApplicationFiled: August 30, 2012Publication date: December 27, 2012Applicant: 1149336 Ontario Inc.Inventor: Daniel J. Drucker
-
Patent number: 8318669Abstract: The present invention provides methods for modification and regulation of glucagon-like peptide 1 (GLP-1) metabolism by administering therapeutically effective amounts of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof, where the inhibitor has a Ki for inhibition of DPIV of 10 nM or less; and the inhibitor is administered in an amount sufficient to inhibit DPIV proteolysis of GLP-1 but not sufficient to suppress the immune system of the animal.Type: GrantFiled: November 9, 2010Date of Patent: November 27, 2012Assignees: Trustees of Tufts College, New England Medical Center Hospitals, Inc., 1149336 Ontario, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
-
Patent number: 8278273Abstract: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.Type: GrantFiled: May 6, 2011Date of Patent: October 2, 2012Assignee: 1149336 Ontario, Inc.Inventor: Daniel J. Drucker
-
Publication number: 20120165252Abstract: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.Type: ApplicationFiled: November 16, 2011Publication date: June 28, 2012Applicants: Trustees of Tufts College, 1149336 Ontario, Inc., New England Medical Center Hospitals, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel J. Drucker
-
Publication number: 20110275568Abstract: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.Type: ApplicationFiled: May 6, 2011Publication date: November 10, 2011Applicant: 1149336 Ontario Inc.Inventor: Daniel J. Drucker
-
Publication number: 20110223108Abstract: Glucagon-like peptide 2, a product of glucagon gene expression, and analogs of glucagon-like peptide 2, have been identified as gastrointestinal tissue growth factors. Their effects on the growth of small bowel and pancreatic islets are described. Their formulation as a pharmaceutical, and their therapeutic use in treating disorders of the bowel, are described.Type: ApplicationFiled: December 22, 2010Publication date: September 15, 2011Applicant: 1149336 Ontario, Inc.Inventor: Daniel J. Drucker
-
Publication number: 20110172149Abstract: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.Type: ApplicationFiled: November 9, 2010Publication date: July 14, 2011Applicants: Trustees of Tufts College, New England Medical Center Hospitals, Inc., 1149336 Ontario, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel Drucker
-
Patent number: 7960344Abstract: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.Type: GrantFiled: October 16, 2009Date of Patent: June 14, 2011Assignee: 1149336 Ontario, Inc.Inventor: Daniel J. Drucker
-
Patent number: 7862824Abstract: The effects of GLP-2 are enhanced using a GLP-1 activity inhibitor. For medical use to treat or inhibit the onset of medical conditions, disorder or diseases for which treatment with GLP-2 is indicated, the present invention provides a pharmaceutical combination comprising a GLP-2 activity enhancer, and a GLP-1 activity inhibitor. The combination is useful particularly to treat gastrointestinal conditions such as small bowel syndrome, mucositis and Crohn's disease, and to suppress appetite, for instance to treat obesity.Type: GrantFiled: April 22, 2004Date of Patent: January 4, 2011Assignee: 1149336 Ontario, Inc.Inventors: Daniel J. Drucker, Julie Ann Louise Lovshin
-
Patent number: 7829530Abstract: One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal but not sufficient to suppress the animal's immune system.Type: GrantFiled: November 26, 2008Date of Patent: November 9, 2010Assignees: Trustees of Tufts College, New England Medical Center Hospitals, 1149336 Ontario, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel Drucker
-
Publication number: 20100119453Abstract: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.Type: ApplicationFiled: October 16, 2009Publication date: May 13, 2010Applicant: 1149336 Ontario Inc.Inventor: Daniel J. Drucker
-
Patent number: 7459428Abstract: One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal.Type: GrantFiled: July 17, 2006Date of Patent: December 2, 2008Assignees: Trustees of Tufts College, New England Medical Center Hospitals, Inc., 1149336 Ontario, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel Drucker